
Following Thursday’s news that Novavax had finally received the sought-after emergency authorization for its Covid-19 vaccine from the US Food and Drug Administration (FDA), the firm dropped 25.1% on the stock exchange.
The vaccine in question goes by Adjuvanted in the US, and is only the fourth vaccine approved for the coronavirus in the country. Some might therefore have thought the news would have received a more warm welcome by investors.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app